In this retrospective cohort analysis, we explored clinical outcomes of patients with unresectable locally advanced NSCLC who received CRT followed by consolidative durvalumab and stratified outcomes by the presence of non–KRAS driver variations, KRAS driver variations, or no driver variations. This evidence concerns the gene KRAS and non-small cell lung carcinoma.